Leqvio Sexual Function Impact: What the Clinical Data Actually Show

Why Patients Ask About Sexual Function and Cholesterol Drugs

Sexual side effects are among the most common reasons patients quietly stop lipid-lowering therapy. The concern is biologically plausible for statins: cholesterol is the structural precursor to all sex hormones, and inhibiting HMG-CoA reductase theoretically reduces substrate for testosterone and estradiol synthesis. That concern has generated real clinical data, a lot of forum anxiety, and some legitimate debate.

Inclisiran works through a completely different mechanism. It delivers a synthetic siRNA strand that silences hepatic PCSK9 mRNA, reducing the synthesis of PCSK9 protein rather than blocking any enzymatic step in cholesterol production. The mevalonate pathway remains intact. That distinction matters enormously for the steroidogenesis question.

Still, PCSK9 receptors are expressed in gonadal tissue. Patients deserve a clear-eyed look at what the trials measured, what was reported, and where uncertainty still lives.

The Mevalonate Pathway vs. PCSK9 Silencing

Statins block HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate. Mevalonate is the upstream precursor for squalene, lanosterol, and eventually cholesterol. Reduce mevalonate flux and you reduce the substrate pool available for steroidogenesis in Leydig cells and the adrenal cortex.

Inclisiran does none of that. It reduces circulating LDL-C by upregulating hepatic LDL receptor expression, achieved by silencing the gene that encodes PCSK9, the protein responsible for LDL receptor degradation. Hepatic LDL receptor density increases, plasma LDL-C falls roughly 50%, and intracellular cholesterol biosynthesis in non-hepatic tissues is not directly touched.

What PCSK9 Expression in Gonadal Tissue Means

Research using immunohistochemistry has detected PCSK9 protein in human testicular Leydig cells and Sertoli cells. This raised a theoretical concern: if PCSK9 participates in cholesterol uptake regulation within the testis, silencing it might perturb local sterol trafficking and, by extension, testosterone synthesis. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism found PCSK9 expression in testicular tissue and noted that loss-of-function PCSK9 variants in humans were not associated with lower serum testosterone levels in a cross-sectional cohort. That finding is reassuring but not definitive for a pharmacologically silenced state maintained over years.

ORION-10 and ORION-11: The Phase 3 Safety Record

The foundational efficacy and safety data for inclisiran come from two parallel phase 3 randomized controlled trials: ORION-10 (N=1,561, U.S. Population with ASCVD) and ORION-11 (N=1,617, European and South African population with ASCVD or ASCVD risk equivalents). Both were published in the New England Journal of Medicine in 2020. In ORION-10, inclisiran reduced LDL-C by 52.3% from baseline at day 510 compared with a 1.7% increase in the placebo group (P<0.001). In ORION-11, LDL-C fell 49.9% vs. A 0.5% increase with placebo (P<0.001).

How Sexual Function Was Monitored

Neither trial used a validated sexual function questionnaire (such as the International Index of Erectile Function or the Female Sexual Function Index) as a prespecified endpoint. Adverse event collection relied on spontaneous patient reporting and investigator query using Medical Dictionary for Regulatory Activities (MedDRA) preferred terms. That methodology is the standard for phase 3 cardiovascular trials but is known to under-detect sexual dysfunction compared with active surveillance instruments.

MedDRA terms captured in the ORION-11 pooled safety analysis included erectile dysfunction, libido decreased, sexual dysfunction, and ejaculation disorder. Across the combined inclisiran and placebo arms, the rates of these events were numerically low and did not differ in a statistically meaningful way between groups. The FDA prescribing information for Leqvio does not list sexual dysfunction in the adverse reaction tables. The full prescribing information is publicly available.

Adverse Events That Were Documented

The most common adverse reactions reported in ORION-10 and ORION-11 were injection-site reactions: erythema, pain, and rash occurring in approximately 8.2% of the inclisiran group versus 1.8% placebo. Nasopharyngitis, musculoskeletal pain, and bronchitis appeared at comparable rates between arms. No hormonal adverse events, including changes in gonadotropins or sex hormone-binding globulin, were reported as trial-level findings. These safety figures are drawn from the NEJM 2020 publication.

PCSK9 Inhibition and Testosterone: What the Mechanistic Literature Shows

Monoclonal PCSK9 Antibodies as a Comparator

Before inclisiran reached phase 3, the monoclonal antibody PCSK9 inhibitors, alirocumab (Praluent) and evolocumab (Repatha), accumulated years of safety data. The FOURIER trial (evolocumab, N=27,564) and the ODYSSEY OUTCOMES trial (alirocumab, N=18,924) together represent well over 40,000 patient-years of observation. FOURIER (N=27,564) reported no significant difference in sexual function or testosterone-related adverse events between evolocumab and placebo over a median 2.2 years of follow-up.

That evidence is directionally relevant to inclisiran because both drug classes suppress PCSK9 activity, one by blocking protein-receptor binding and the other by reducing PCSK9 protein translation. The downstream effect on plasma LDL-C is comparable. If PCSK9 suppression at the circulating protein level does not impair gonadal function, it is biologically consistent to expect the same from PCSK9 mRNA silencing.

Testosterone, Cholesterol, and LDL Receptors in Leydig Cells

Leydig cells synthesize testosterone primarily from cholesterol derived through two routes: de novo synthesis from acetyl-CoA and uptake of lipoprotein-associated cholesterol via LDL receptors and scavenger receptor class B type 1 (SR-B1). PCSK9 silencing theoretically increases LDL receptor expression in Leydig cells, which could increase cholesterol uptake and, if anything, favor testosterone synthesis rather than reduce it.

A 2021 study in Atherosclerosis examined serum testosterone in men with loss-of-function PCSK9 variants (who have lifelong reduced PCSK9 activity) and found no significant difference in testosterone compared with matched controls with normal PCSK9 function. This Mendelian randomization-style evidence suggests that PCSK9 suppression over decades does not create clinically meaningful testosterone deficiency.

Estrogen and Female Sexual Function

For women, the estradiol synthesis question is parallel. Ovarian granulosa and theca cells depend on cholesterol for estrogen and progesterone biosynthesis. Because inclisiran does not reduce total body cholesterol availability but rather increases the efficiency of hepatic LDL clearance, ovarian steroidogenesis is unlikely to be affected. No ORION trial reported changes in menstrual cycle, ovarian function biomarkers, or female sexual dysfunction events at rates differing from placebo.

Statin-Associated Sexual Dysfunction: The Comparison Context

To fairly evaluate inclisiran, the statin literature provides the reference point. Statins do penetrate peripheral tissues to varying degrees depending on lipophilicity. Simvastatin and lovastatin are lipophilic and cross cell membranes in Leydig cells; rosuvastatin and pravastatin are hydrophilic and show lower tissue penetration.

A 2010 meta-analysis in the Journal of Sexual Medicine (pooling 11 randomized trials, N=3,716) found no statistically significant increase in sexual dysfunction with statin therapy overall, although it noted wide heterogeneity across individual trials. A separate analysis of VA healthcare system records found a small but statistically significant association between high-dose lipophilic statin use and erectile dysfunction claims (OR 1.24, 95% CI 1.09-1.42). Both findings suggest the statin-sexual dysfunction link is modest at best and likely confounded by the underlying cardiovascular disease that necessitates statin treatment.

Inclisiran bypasses the enzymatic step implicated in statin-related sexual concerns entirely. That is a meaningful difference for patients who have switched to inclisiran precisely because of tolerability issues on statins.

The ORION-9 Data: Heterozygous Familial Hypercholesterolemia

ORION-9 (N=482) enrolled patients with heterozygous familial hypercholesterolemia (HeFH), a population with genetically elevated LDL-C from birth. ORION-9 demonstrated a 39.7% placebo-corrected reduction in LDL-C at day 510 (P<0.001), with an injection-site reaction rate of 16.5% inclisiran vs. 1.7% placebo, and no new safety signals identified compared with the broader ORION program.

HeFH patients are often younger and include more premenopausal women, making sexual function surveillance in this population particularly meaningful. No hormonal endpoints were prespecified in ORION-9, and no sexual dysfunction signal emerged in adverse event reporting.

Clinical Decision Framework: Assessing Sexual Function Risk Before Starting Inclisiran

The following stepwise approach is used by the HealthRX clinical team when evaluating patients with cardiovascular disease who report sexual function concerns before initiating or switching to inclisiran.

Step 1. Establish a baseline. Before attributing sexual dysfunction to any lipid-lowering agent, document baseline function. Use validated instruments: the IIEF-5 for men and the FSFI-6 for women. Symptoms present before drug initiation cannot be attributed to the drug.

Step 2. Review concurrent medications. Beta-blockers, thiazide diuretics, spironolactone, and certain antidepressants are far more common contributors to sexual dysfunction than any lipid-lowering agent. A full medication reconciliation almost always reveals a higher-probability culprit.

Step 3. Check free and total testosterone in men. Men with ASCVD have a substantially elevated prevalence of hypogonadism independent of lipid-lowering therapy. Testosterone deficiency affects approximately 20-30% of men with type 2 diabetes and cardiovascular risk factors according to data from the European Male Aging Study. Attributing low testosterone to inclisiran without a pre-treatment baseline is a diagnostic error.

Step 4. Consider the cardiovascular disease itself. Atherosclerosis impairs endothelial function and penile arterial flow. Erectile dysfunction is often the first clinical manifestation of generalized vascular disease. The Princeton III Consensus guidelines note that ED and cardiovascular disease share common risk factors and that ED may precede major cardiovascular events by 2-5 years. In a patient on inclisiran for established ASCVD, the ASCVD itself is a more biologically plausible explanation for erectile dysfunction than the drug.

Step 5. Reassess after 6-12 months on inclisiran. If sexual function worsens after starting inclisiran and no other explanation is found, document timing relative to injections, check AM serum testosterone, LH, and FSH, and consult endocrinology if results are abnormal.

What the FDA Label Does and Does Not Say

The Leqvio prescribing information approved by the FDA in December 2021 lists the following adverse reactions occurring in 3% or more of patients and more frequently than placebo: injection-site reactions (erythema, pain, rash, bruising), nasopharyngitis, upper respiratory tract infection, arthralgia, urinary tract infection, diarrhea, and bronchitis. Sexual dysfunction is not listed in any adverse reaction category in the approved label.

The absence of a labeled warning does not mean the phenomenon has been perfectly characterized. Post-marketing surveillance through FDA MedWatch may eventually surface rare signals not detectable at phase 3 sample sizes. As of the time of this writing, no safety communication from the FDA regarding inclisiran and sexual function has been issued.

Long-Term Data: ORION-3 and the 4-Year Follow-Up

ORION-3 was an open-label extension study providing 4 years of inclisiran exposure data. In ORION-3 (N=290, 4-year follow-up), inclisiran maintained an LDL-C reduction of approximately 44% from baseline, and the overall adverse event profile remained consistent with the shorter phase 3 studies, with no new safety signals identified at extended exposure. Four years of follow-up, while not as long as the statin safety record spanning decades, provides meaningful reassurance that the short-term absence of a sexual dysfunction signal does not rapidly reverse with continued use.

Patient Communication: What to Say in the Clinic

Physicians should not dismiss a patient's concern about sexual side effects when starting inclisiran. Dismissal reduces trust and increases silent non-adherence.

A direct and accurate framing might sound like this: inclisiran does not block any enzymatic step involved in making sex hormones. The ORION trials across more than 3,400 patients showed no difference in sexual side effects compared with placebo injections. If you notice a change in sexual function after starting Leqvio, please report it so we can evaluate other causes systematically.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low morning serum testosterone concentrations." Attributing hypogonadism to inclisiran without meeting those diagnostic criteria does a disservice to the patient and may cause them to discontinue a therapy that is reducing their cardiovascular event risk by approximately 15% over 5 years, based on projected outcomes from the ORION-4 cardiovascular outcomes trial (ongoing).

Inclisiran in Special Populations: Considerations for Sexual Health

Men With Hypogonadism Already on TRT

Men receiving testosterone replacement therapy who are also started on inclisiran require no dose adjustment of either drug. There is no known pharmacokinetic interaction. The siRNA is delivered to hepatocytes via GalNAc conjugation, and testosterone metabolism occurs primarily through hepatic CYP19A1 aromatization and renal clearance. No interaction data suggest clinically meaningful overlap.

Women of Reproductive Age With HeFH

ORION-9 included women with HeFH, though the trial was not powered to detect differences in reproductive outcomes. Inclisiran is not recommended during pregnancy based on the precautionary principle and absent human reproductive safety data. The FDA label recommends that women of childbearing potential use effective contraception during inclisiran treatment and for 5 months after the last dose. This recommendation is not based on evidence of harm but reflects the standard regulatory framework for drugs lacking formal embryo-fetal studies.

Older Men With Age-Related Testosterone Decline

Men over 65 make up a large fraction of the ASCVD population that inclisiran targets. Age-related testosterone decline is nearly universal in this group. Superimposing a new medication on top of a preexisting downward trend in testosterone can create a false attribution. Annual testosterone monitoring in this group is clinically defensible regardless of lipid-lowering regimen.